Get real-time Day One Biopharmaceuticals (DAWN) stock price quotes, analyst insights, forecasts, news, and information you need to help your stock trading and investing.
用富途牛牛查看Day One Biopharmaceuticals(DAWN)的股票价格、即时报价、最新新闻、历史走势图、财务信息和行情。
DAWN Stock Price 1D 5D 1M 6M YTD 1Y 5Y 10Y MAX Basic Advanced -22.79% Day One Biopharmaceuticals, Inc. price and volume Combination chart with 2 data series. Chart represents Day One Biopharmaceuticals, Inc. price and volume over 1Y period The...
Day One Biopharmaceuticals (DAWN) Stock Price & Analysis Follow 302 FollowersPortfolio DAWN Stock Chart & Stats Advanced Chart > 1d5d 3m -20.92%6mYTD1y3y5y Day’s Range―- ― 52-Week Range$11.13 - $18.07 Previous CloseN/A Volume175.11K Average Volume (3M)1.09M Market Cap $1.13B Ente...
Needham:重申Day One Biopharmaceutical(DAWN.US)评级,由买入调整至买入评级, 目标价由32.00美元调整至32.00美元。 Day One Biopharmaceuticals(DAWN.US)公司简介:Day One biopharmacics Inc 是一家临床阶段的生物制药公司。公司致力于开发和商业化针对全年龄的遗传性癌症患者的靶向治疗。最初,公司专注于儿科癌症患者的临...
Day One Biopharmaceuticals Inc. options data by MarketWatch. View DAWN option chain data and pricing information for given maturity periods.
Day One Biopharmaceuticals (DAWN) Posts Stellar Q3 but with Extreme Concentration Risk Dec 17, 2024 • TipRanks Stocks Day One price target lowered to $34 from $39 at JonesResearch Dec 16, 2024 • TipRanks Stocks Day One Biopharmaceuticals Announces Leadership Transition Nov 20, 2024...
{}Today, we circle back toDay OneBiopharmaceuticals as the company's stock has dropped some even after its first FDA approval in late April.Analysts are optimistic about Day One Biopharmaceuticals, with numerous buy ratings and price targets ranging from $33 to $40 a share. The stock currently...
Day One Biopharmaceuticals, Inc. announced the closing on June 12, 2023 of its previously announced underwritten public offering of 13,269,231 shares of its common stock, including the full exercise of the underwriters’ option to purchase 1,730,769 additi...
Currently, the analyst consensus on Day One Biopharmaceuticals is a Strong Buy with an average price target of $38.13, which is a 175.3% upside from current levels. In a report issued on April 9, JonesTrading also maintained a Buy rating on the stock with a $35.00 pr...